Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Feature|Articles|September 10, 2026
AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs
Author(s)Marco Meglio
The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.
Advertisement
Advertisement
The American Academy of Neurology (AAN) and American Headache Society (AHS) have issued an updated practice guideline on pharmacologic migraine prevention in adults, published in Neurology and replacing recommendations last updated in 2012.1,2 Drawing on a systematic review of evidence through June 6, 2024, the guideline reflects newer preventive drug classes, including CGRP-targeted therapies, and offers graded recommendations on when to start preventive therapy, how to choose among medications, and how to manage treatment in populations such as pregnant or lactating patients, older adults, and those with comorbidities or medication overuse.1,3
Related to this article
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.
New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.
Advertisement
Advertisement